Comprehensive Analysis of Enhancer RNAs Identifies LINC00689 and ELFN1-AS1 As Novel Prognostic Biomarkers in Uveal Melanoma

Overview

Journal Dis Markers

Publisher Wiley

Specialty Biochemistry

Date 2022 Mar 7

PMID 35251374

Authors

Su Zhao

Hao Jiang

Jing Liu

Dao-Yuan Li

Bing Li

Qiu-Rong Long

Lei Zheng

Hao Gu

Affiliations

Soon will be listed here.

Abstract

Enhancer RNAs (eRNAs) have emerged as key players in the pathology of several tumors, including uveal melanoma. Here, we aimed to explore the prognostic values of eRNAs in uveal melanoma (UVM) patients. The expressing data and survival data of UVM patients were downloaded from TCGA and GSE22138 datasets. The Kaplan-Meier methods with the log-rank test were applied to screen survival-related eRNAs in UVM. GEPIA was applied to analyze the associations between expressions of eRNA and disease-free survival. KEGG assays were applied to explore the potential signaling pathways of the key eRNA. The prognostic values of eRNAs were further explored by multivariate assays by the R package survival. The eRNAs were validated in pan-cancer. In this study, we identified 89 survival-related eRNAs in UVM based on TCGA datasets. Based on GSE22138 datasets, we found 27 survival-related eRNAs in UVM. Only two eRNAs (LINC00689 and ELFN1-AS1) were overlapped in both two datasets. The results of multivariate analysis revealed that both LINC00689 and ELFN1-AS1 were independent prognostic factors in UVM patients. The pan-cancer validation results further confirmed the prognostic values of LINC00689 and ELFN1-AS1 in eight tumors. Overall, we identified two novel UVM-related eRNAs, LINC00689 and ELFN1-AS1 which may serve as prognostic and diagnostic biomarkers of UVM patients for clinical decision-making.

References

Ortega M, Fraile-Martinez O, Garcia-Honduvilla N, Coca S, Alvarez-Mon M, Bujan J . Update on uveal melanoma: Translational research from biology to clinical practice (Review). Int J Oncol. 2020; 57(6):1262-1279. PMC: 7646582. DOI: 10.3892/ijo.2020.5140. View

Ye R, Cao C, Xue Y . Enhancer RNA: biogenesis, function, and regulation. Essays Biochem. 2020; 64(6):883-894. DOI: 10.1042/EBC20200014. View

Jie Y, Ye L, Chen H, Yu X, Cai L, He W . ELFN1-AS1 accelerates cell proliferation, invasion and migration via regulating miR-497-3p/CLDN4 axis in ovarian cancer. Bioengineered. 2020; 11(1):872-882. PMC: 8291874. DOI: 10.1080/21655979.2020.1797281. View

Saeidian A, Youssefian L, Vahidnezhad H, Uitto J . Research Techniques Made Simple: Whole-Transcriptome Sequencing by RNA-Seq for Diagnosis of Monogenic Disorders. J Invest Dermatol. 2020; 140(6):1117-1126.e1. PMC: 8722382. DOI: 10.1016/j.jid.2020.02.032. View

Jager M, Shields C, Cebulla C, Abdel-Rahman M, Grossniklaus H, Stern M . Uveal melanoma. Nat Rev Dis Primers. 2020; 6(1):24. DOI: 10.1038/s41572-020-0158-0. View

Che W, Ye S, Cai A, Cui X, Sun Y . CRISPR-Cas13a Targeting the Enhancer RNA-SMAD7e Inhibits Bladder Cancer Development Both and . Front Mol Biosci. 2020; 7:607740. PMC: 7705062. DOI: 10.3389/fmolb.2020.607740. View

Kopp F, Mendell J . Functional Classification and Experimental Dissection of Long Noncoding RNAs. Cell. 2018; 172(3):393-407. PMC: 5978744. DOI: 10.1016/j.cell.2018.01.011. View

Smit K, Jager M, de Klein A, Kili E . Uveal melanoma: Towards a molecular understanding. Prog Retin Eye Res. 2019; 75:100800. DOI: 10.1016/j.preteyeres.2019.100800. View

Li Y, Jia R, Ge S . Role of Epigenetics in Uveal Melanoma. Int J Biol Sci. 2017; 13(4):426-433. PMC: 5436563. DOI: 10.7150/ijbs.18331. View

10.

Wang J, Zhu S, Meng N, He Y, Lu R, Yan G . ncRNA-Encoded Peptides or Proteins and Cancer. Mol Ther. 2019; 27(10):1718-1725. PMC: 6822234. DOI: 10.1016/j.ymthe.2019.09.001. View

11.

Xue Z, Cui C, Liao Z, Xia S, Zhang P, Qin J . Identification of LncRNA Linc00513 Containing Lupus-Associated Genetic Variants as a Novel Regulator of Interferon Signaling Pathway. Front Immunol. 2019; 9:2967. PMC: 6305415. DOI: 10.3389/fimmu.2018.02967. View

12.

Chen H, Liang H . A High-Resolution Map of Human Enhancer RNA Loci Characterizes Super-enhancer Activities in Cancer. Cancer Cell. 2020; 38(5):701-715.e5. PMC: 7658066. DOI: 10.1016/j.ccell.2020.08.020. View

13.

Shigeyasu K, Toden S, Ozawa T, Matsuyama T, Nagasaka T, Ishikawa T . The PVT1 lncRNA is a novel epigenetic enhancer of MYC, and a promising risk-stratification biomarker in colorectal cancer. Mol Cancer. 2020; 19(1):155. PMC: 7643275. DOI: 10.1186/s12943-020-01277-4. View

14.

Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z . GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017; 45(W1):W98-W102. PMC: 5570223. DOI: 10.1093/nar/gkx247. View

15.

Lee J, Xiong F, Li W . Enhancer RNAs in cancer: regulation, mechanisms and therapeutic potential. RNA Biol. 2020; 17(11):1550-1559. PMC: 7567500. DOI: 10.1080/15476286.2020.1712895. View

16.

Boon R, Jae N, Holdt L, Dimmeler S . Long Noncoding RNAs: From Clinical Genetics to Therapeutic Targets?. J Am Coll Cardiol. 2016; 67(10):1214-1226. DOI: 10.1016/j.jacc.2015.12.051. View

17.

Yu G, Wang L, Han Y, He Q . clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 2012; 16(5):284-7. PMC: 3339379. DOI: 10.1089/omi.2011.0118. View

18.

Bose D, Berger S . eRNA binding produces tailored CBP activity profiles to regulate gene expression. RNA Biol. 2017; 14(12):1655-1659. PMC: 5731803. DOI: 10.1080/15476286.2017.1353862. View

19.

Hand F, Doherty S, Gullo G, Geoghegan J, Crown J, Hoti E . Metastatic uveal melanoma: A valid indication for liver resection. J BUON. 2020; 25(2):1161-1165. View

20.

Nikas J . Independent validation of a mathematical genomic model for survival of glioma patients. Am J Cancer Res. 2016; 6(6):1408-19. PMC: 4937742. View